PMID: 9431919Feb 12, 1998Paper

Comparison of ATB staph, rapid ATB staph, Vitek, and E-test methods for detection of oxacillin heteroresistance in staphylococci possessing mecA

Journal of Clinical Microbiology
N B FrebourgJ F Lemeland

Abstract

The performance characteristics of the E-test (AB Biodisk, Solna, Sweden), the ATB Staph, the Rapid ATB Staph, and the Vitek GPS-503 card (bioMérieux, La Balme Les Grottes, France) methods for the detection of oxacillin resistance in a collection of staphylococci with a high proportion of troublesome strains were evaluated. Sixty-four Staphylococcus aureus strains and 76 coagulase-negative staphylococcal strains were tested. All strains were mecA positive and were characterized by the oxacillin agar screen plate test; 75 (53.6%) were found to be heterogeneous by a large-inoculum oxacillin disk diffusion assay, and oxacillin MICs for 89 (63.6%) were < or = 32 microg/ml. Three (4.7%) S. aureus strains and 25 (32.9%) coagulase-negative strains were classified as susceptible by the E-test, as defined by the National Committee for Clinical Laboratory Standards (NCCLS) oxacillin breakpoint (MIC < or = 2 microg/ml). The ATB Staph method failed to detect oxacillin resistance in 7 (11%) S. aureus isolates and 32 (42.1%) coagulase-negative isolates. The MICs for all but six of these discrepant isolates were < or = 16 microg/ml. The Rapid ATB Staph method was tested against S. aureus strains only and yielded 15 (23.4%) false-susceptible r...Continue Reading

References

Jan 1, 1992·Antimicrobial Agents and Chemotherapy·C RyffelB Berger-Bächi
Jul 1, 1992·Journal of Clinical Microbiology·S UnalP L Skatrud
Sep 1, 1990·Antimicrobial Agents and Chemotherapy·G L Archer, E Pennell
Jul 1, 1989·Antimicrobial Agents and Chemotherapy·C J Hackbarth, H F Chambers
Apr 1, 1995·Antimicrobial Agents and Chemotherapy·C L McDonaldR J Fass
Jul 1, 1994·Journal of Clinical Microbiology·D J GehaD H Persing
Nov 1, 1995·Journal of Clinical Microbiology·P VannuffelJ L Gala
May 1, 1996·The Journal of Antimicrobial Chemotherapy·F WalletR J Courcol
Aug 1, 1996·FEMS Microbiology Letters·S Píriz DuránB Berger-Bächi
Sep 1, 1996·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·G ZambardiA Viebahn
Feb 1, 1997·The Journal of Antimicrobial Chemotherapy·T M WellerJ B Selkon

❮ Previous
Next ❯

Citations

Apr 8, 2010·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·P BemerS Corvec
Oct 25, 2013·Journal of Clinical Microbiology·Carmen L GiltnerRomney M Humphries
Oct 8, 1999·The Journal of Antimicrobial Chemotherapy·M De GiustiC Chiesa
Jul 8, 2011·Clinical Microbiology Reviews·Trevor Winstanley, Patrice Courvalin
Nov 19, 2005·The Journal of Antimicrobial Chemotherapy·Derek F J BrownUNKNOWN Infection Control Nurses Association
Jan 9, 2015·Clinical Microbiology Reviews·Omar M El-Halfawy, Miguel A Valvano
Jun 27, 2019·Nature Reviews. Microbiology·Dan I AnderssonKarin Hjort
Sep 11, 2003·Clinical Orthopaedics and Related Research·Ivan S TarkinKevin L Garvin
Jul 16, 1999·Journal of Clinical Microbiology·M Pestel-CaronJ F Lemeland
Aug 17, 1999·Journal of Clinical Microbiology·A van GriethuysenJ Kluytmans
Apr 29, 2004·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Y TvetenB-E Kristiansen
Feb 1, 2005·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C NonhoffM J Struelens
Nov 24, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·I NahimanaD S Blanc

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.